Publication | Open Access

S-1/temozolomide versus S-1/temozolomide plus thalidomide in advanced pancreatic and non-pancreatic neuroendocrine tumours (STEM): A randomised, open-label, multicentre phase 2 trial

Neuro-oncologyEndocrine OncologySurgical OncologyOncologyPancreatic CancerMulticentre Phase 2Non-pancreatic Neuroendocrine TumoursMedicineS-1/temozolomide Versus S-1/temozolomidePharmacologyRadiation Oncology